{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:54:06Z","timestamp":1793832846459,"version":"4.6.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"PROSPECT II"},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Infrared"},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Apolipoprotein B (apoB)-containing lipoproteins contribute heterogeneously to atherosclerosis. While apoB particles are major determinants of plaque burden, Lp(a) has been linked to plaque inflammation and instability. We investigated the associations of non-Lp(a) apoB, Lp(a), and their relative balance with coronary plaque burden and vulnerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Among 854 patients with recent myocardial infarction enrolled in the PROSPECT II near-infrared spectroscopy\u2013intravascular ultrasound (NIRS-IVUS) study, total apoB was converted to nmol\/L and non-Lp(a) apoB calculated by subtracting Lp(a) in nmol\/L. The non-Lp(a) apoB\/Lp(a) ratio was used to characterize the relative predominance of these lipoprotein classes. Higher non-Lp(a) apoB was independently associated with greater plaque burden [plaque percentage volume; \u03b2 = 0.19, 95% confidence interval (CI) 0.05\u20130.33; P = 0.009], but not with lipid core burden index. In contrast, lower non-Lp(a) apoB\/Lp(a) ratio tertile were associated with higher odds of plaque burden \u226570% [odds ratio (OR) 1.47, 95% CI 1.04\u20132.07; P = 0.029] and the composite vulnerability endpoint of plaque burden \u226570% and maxLCBI4mm \u2265324.7 (OR 1.62, 95% CI 1.12\u20132.33; P = 0.011). In an exploratory external cohort from the CASABLANCA study, lower ratios identified an Lp(a)- and oxidized phospholipid-enriched phenotype and were associated with higher unadjusted cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Non-Lp(a) apoB and Lp(a) demonstrate distinct associations with coronary plaque burden and vulnerability. Differentiating Lp(a)-associated from non-Lp(a)-associated apoB particle pools provides complementary information on coronary plaque phenotype, and the non-Lp(a) apoB\/Lp(a) ratio summarizes their relative predominance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Information<\/jats:title>\n                    <jats:p>PROSPECT II- https:\/\/ClinicalTrial.gov Identifier: NCT02171065<\/jats:p>\n                    <jats:p>CASABLANCA- https:\/\/ClinicalTrial.gov Identifier: NCT00842868.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>One-sentence summary<\/jats:title>\n                    <jats:p>In patients with recent heart attack, the balance between conventional cholesterol-carrying particles and lipoprotein(a) identifies different types of coronary artery disease phenotypes and may help explain why some plaques are more likely to become dangerous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Conventional apoB-containing lipoproteins (primarily LDL-related particles) were associated with greater overall coronary plaque burden, whereas a relative predominance of lipoprotein(a) was associated with plaques that had features linked to a higher risk of future cardiovascular events. A simple ratio comparing non-lipoprotein(a) apoB particles with lipoprotein(a) particles summarized these distinct biological processes and may provide complementary information for future studies evaluating cardiovascular risk and therapies targeting lipoprotein(a).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag512","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:21:23Z","timestamp":1790425283000},"source":"Crossref","is-referenced-by-count":5,"title":["Balance of non-Lp(a) apoB and Lp(a) with coronary plaque phenotypes and MACE: insights from PROSPECT II and CASABLANCA"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California San Diego , 9500 Gilman Drive, BSB 1080, La Jolla, CA 92093-0682 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1798","authenticated-orcid":false,"suffix":"Jr","given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Baim Institute for Clinical Research, Cardiology Division, Massachusetts General Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-6433","authenticated-orcid":false,"given":"Michael","family":"Maeng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-9194","authenticated-orcid":false,"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0819-5792","authenticated-orcid":false,"given":"Lars","family":"Kj\u00f8ller-Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zealand University Hospital , Roskilde ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Ben-Yehuda","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California San Diego , 9500 Gilman Drive, BSB 1080, La Jolla, CA 92093-0682 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-0247","authenticated-orcid":false,"given":"Mitsuaki","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-8962","authenticated-orcid":false,"given":"Hans Erik","family":"B\u00f8tker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-345X","authenticated-orcid":false,"given":"Ole","family":"Fr\u00f6bert","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Health, \u00d6rebro University, Sweden and Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6722-8745","authenticated-orcid":false,"given":"Jonas","family":"Persson","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Department of Clinical Sciences, Danderyd University Hospital, Division of Cardiovascular Medicine , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Wiseth","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology, St. Olavs University Hospital , Trondheim ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9141-0499","authenticated-orcid":false,"given":"Alf I","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Stavanger University Hospital , Stavanger ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-2429","authenticated-orcid":false,"given":"Lisette O","family":"Jensenk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan E","family":"Nordrehaug","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-8707","authenticated-orcid":false,"given":"\u00d8yvind","family":"Bleie","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen , Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-8621","authenticated-orcid":false,"given":"Elmir","family":"Omerovic","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine\/Cardiology, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-7404","authenticated-orcid":false,"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Cardiology, Uppsala University and Uppsala Clinical Research Center , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-3786","authenticated-orcid":false,"given":"Rebecca","family":"Rylance","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[{"name":"Baim Institute for Clinical Research, Cardiology Division, Massachusetts General Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-9736","authenticated-orcid":false,"given":"Stefan K","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Cardiology, Uppsala University and Uppsala Clinical Research Center , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-3197","authenticated-orcid":false,"given":"Ziad A","family":"Ali","sequence":"additional","affiliation":[{"name":"St Francis Hospital & Heart Center, Roslyn, NY ,","place":["USA"]},{"name":"New York Institute of Technology , Old Westbury, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-8447","authenticated-orcid":false,"given":"Akiko","family":"Maehara","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation , New York, NY ,","place":["USA"]},{"name":"St Francis Hospital & Heart Center, Roslyn, NY ,","place":["USA"]},{"name":"New York Institute of Technology , Old Westbury, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-8210","authenticated-orcid":false,"given":"Gregg W","family":"Stone","sequence":"additional","affiliation":[{"name":"Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5766","authenticated-orcid":false,"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026101210163135100_zwag512-B1","doi-asserted-by":"crossref","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels international declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026101210163135100_zwag512-B2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026101210163135100_zwag512-B3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026101210163135100_zwag512-B4","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the national lipid association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026101210163135100_zwag512-B5","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2025.04.013","article-title":"Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques: a PROSPECT II substudy","volume":"85","author":"Erlinge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026101210163135100_zwag512-B6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2026101210163135100_zwag512-B7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","article-title":"Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study","volume":"397","author":"Erlinge","year":"2021","journal-title":"Lancet"},{"key":"2026101210163135100_zwag512-B8","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","article-title":"Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes","volume":"81","author":"Gilliland","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026101210163135100_zwag512-B9","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1073\/pnas.85.6.1772","article-title":"Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine","volume":"85","author":"Higuchi","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101210163135100_zwag512-B10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0022-2275(20)30267-4","article-title":"Structure of apolipoprotein B-100 in low density lipoproteins","volume":"42","author":"Segrest","year":"2001","journal-title":"J Lipid Res"},{"key":"2026101210163135100_zwag512-B11","doi-asserted-by":"crossref","first-page":"100239","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J Lipid Res"},{"key":"2026101210163135100_zwag512-B12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.RA120000830","article-title":"Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a)","volume":"61","author":"Gonen","year":"2020","journal-title":"J Lipid Res"},{"key":"2026101210163135100_zwag512-B13","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"2026101210163135100_zwag512-B14","doi-asserted-by":"crossref","first-page":"100585","DOI":"10.1016\/j.jlr.2024.100585","article-title":"Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease","volume":"65","author":"Bellomo","year":"2024","journal-title":"J Lipid Res"},{"key":"2026101210163135100_zwag512-B15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034774","article-title":"Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study","volume":"13","author":"Januzzi","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026101210163135100_zwag512-B16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026101210163135100_zwag512-B17","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J Lipid Res"},{"key":"2026101210163135100_zwag512-B18","first-page":"100382","article-title":"Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: an optical coherence tomography study","volume":"24","author":"Muramatsu","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026101210163135100_zwag512-B19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2022.03.033","article-title":"Elevated lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: insights from the REASSURE-NIRS registry","volume":"349","author":"Nakamura","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026101210163135100_zwag512-B20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10554-022-02736-3","article-title":"Lipoprotein (a) is related to in-stent neoatherosclerosis incidence rate and plaque vulnerability: optical coherence tomography study","volume":"39","author":"Yuan","year":"2023","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026101210163135100_zwag512-B21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/STROKEAHA.122.042323","article-title":"Lipoprotein(a) is associated with the progression and vulnerability of new-onset carotid atherosclerotic plaque","volume":"54","author":"Duan","year":"2023","journal-title":"Stroke"},{"key":"2026101210163135100_zwag512-B22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026101210163135100_zwag512-B23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101210163135100_zwag512-B24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"2026101210163135100_zwag512-B25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101210163135100_zwag512-B26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026101210163135100_zwag512-B27","first-page":"64","article-title":"Coronary plaque characteristics assessed by optical coherence tomography and plasma lipoprotein(a) levels in patients with acute coronary syndrome","volume":"106","author":"Di Muro","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026101210163135100_zwag512-B28","doi-asserted-by":"crossref","first-page":"e014611","DOI":"10.1161\/CIRCIMAGING.122.014611","article-title":"Association of lipoprotein (a) with coronary-computed tomography angiography-assessed high-risk coronary disease attributes and cardiovascular outcomes","volume":"15","author":"Dai","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026101210163135100_zwag512-B29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026101210163135100_zwag512-B30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCULATIONAHA.105.575241","article-title":"Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas heart study","volume":"113","author":"Khera","year":"2006","journal-title":"Circulation"},{"key":"2026101210163135100_zwag512-B31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/eurjpc\/zwaf088","article-title":"Elevated lipoprotein(a) is not linked to coronary artery calcification incidence or progression","volume":"32","author":"Sung","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026101210163135100_zwag512-B32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jacc.2006.03.047","article-title":"Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries","volume":"48","author":"Hartmann","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026101210163135100_zwag512-B33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018023","article-title":"Association of serum lipoprotein (a) levels and coronary atheroma volume by intravascular ultrasound","volume":"9","author":"Huded","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026101210163135100_zwag512-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"2026101210163135100_zwag512-B35","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2026101210163135100_zwag512-B36","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - A long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101210163135100_zwag512-B37","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag512\/71403492\/zwag512.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag512\/71403492\/zwag512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:16:44Z","timestamp":1791814604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag512\/8836695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag512","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"article-number":"zwag512"}}